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Medical therapy for renal cystic 
disease
In autosomal-dominant polycystic kidney disease (ADPKD), 
excessive proliferation of renal epithelial cells leads to cysts 
that eventually replace most of the normal tissue and cause 
renal failure. Mutations in the PKD1 gene, which encodes 
polycystin-1 (PC1), account for more than 85% of ADPKD 
cases. PC1 is a multispanning membrane protein with a 
C-terminal cytoplasmic tail which has been implicated 
in several signaling pathways. Recent evidence suggests 
that PC1 may also play a role in cilia-mediated sensing of 
luminal fl uid fl ow by renal epithelial cells. However, it is 
unknown which of these proposed functions is critical for 
renal cyst formation. Mutations in several genes unrelated 
to PC1 can also lead to a renal cystic phenotype in animal 
models and humans, but it is unclear whether all of these 
genotypes may converge on a common pathway that is 
critical for cyst formation. If such a common pathway 
exists, it would provide an excellent target for treatment 
strategies. Shillingford et al. examined the possibility 
that PC1 may act in a common pathway with tuberin, 
the product of the tuberous sclerosis complex 2 (TSC2) 
gene.1 TSC2 mutations lead to tuberous sclerosis, a disease 
characterized by renal cysts and benign tumors in multiple 
organs. Tuberin regulates the kinase activity of mTOR, 
which has essential roles in protein translation, cell growth, 
and proliferation. A possible role of mTOR in renal cystic 
disease is supported by two recent reports indicating that 
an inhibitor of mTOR slows disease progression in the Han:
SPRD rat model.2 Indeed, Shillingford et al. found that the 
C-terminal cytoplasmic tail of PC1 interacts with tuberin. 
Th e mTOR pathway is inappropriately activated in cyst-
lining epithelial cells in human ADPKD and three mouse 
models with diff erent aff ected genes, suggesting that this 
is a common, convergent event during renal cystogenesis. 
Shillingford et al. also found that rapamycin, a clinically 
used drug and a specifi c mTOR inhibitor, was highly 
eff ective in reducing cystogenesis in two mouse models of 
polycystic kidney disease and reduced renal size in end-stage 
ADPKD patients aft er renal transplantation. Th ese results 
indicate that dysregulation of mTOR underlies changes in 
renal epithelial cells that cause the formation of polycystic 
kidneys in multiple genetic backgrounds. Th ey also provide 
a mechanistic link among PC1, tuberin, and mTOR, 
suggesting that rapamycin and related drugs that target the 
mTOR pathway are excellent candidates for a therapeutic 
approach to prevent or delay the onset of polycystic kidney 
disease. (1Proc Natl Acad Sci USA 2006; 103: 5466–5471. 
2J Am Soc Nephrol 2005; 16: 46–51) 
Juan Oliver
Neuropsychological and renal 
effects of dental amalgam in 
children
Th ere is concern that exposure to mercury released by 
amalgam dental restorations causes adverse health eff ects, 
but no randomized trials have examined this premise to 
date. Two clinical trials recently reported examined the 
neuropsychological and renal eff ects of dental amalgam in 
children. In the new study by Bellinger et al.,1 534 children 
aged 6–10 years at baseline were randomly assigned to 
receive either amalgam (n = 267) or resin composite (n = 
267) materials for dental restoration. Th e amalgam group 
had signifi cantly higher mean urinary mercury levels, but 
no statistically signifi cant diff erences were found either 
in the IQ scores and other neurocognitive test results or 
in urinary albumin aft er 5 years. In a similarly designed 
study from Lisbon, Portugal, reported by DeRouen et al.,2 
507 children aged 8–10 years were followed for 7 years; 
again, despite higher urinary mercury in the amalgam 
group, there were no statistically signifi cant diff erences 
between the groups’ scores on neurobehavioral assessment 
or nerve conduction velocity tests. In a related editorial, 
the important information provided by these studies was 
acknowledged and the studies’ limitations discussed, 
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including the limited follow-up period, the possibility that 
small eff ects might have been missed owing to statistical 
underpowering, and the fact that certain subsets of patients 
could be more vulnerable than others to the eff ects of 
mercury. (1JAMA 2006; 295: 1775–1783; 2JAMA 2006; 295: 
1784–1792)
Jai Radhakrishnan
Predictive value of urinary 
proteome analysis
Proteome analysis is starting to be used for identifi cation of 
biomarkers for diagnosis of diseases or disease staging. In 
addition, noninvasive proteomics could be used for prognosis 
of medical conditions. Congenital unilateral neonatal 
ureteropelvic junction (UPJ) obstruction can be detected 
by echography in utero, and it is a common clinical problem 
aft er birth. Th e critical issue in infants with UPJ obstruction 
is determining whether corrective surgery is indicated. 
Currently, this oft en requires prolonged medical surveillance, 
including repetitive invasive diuretic renograms that rely on 
arbitrary threshold values. In addition, during surveillance, 
the obstruction might initiate processes that reduce nephron 
numbers. Urinary markers for UPJ obstruction have been 
identifi ed, but their prognostic value in terms of informing 
the decision to operate has not been shown. Using an 
on-line combination of capillary electrophoresis and mass 
spectrometry (CE-MS), Decramer et al. analyzed urinary 
polypeptides from individuals with neonatal UPJ obstruction 
to predict which individuals with this condition would 
evolve toward obstruction that needed surgical correction. 
Th ey identifi ed polypeptides that enabled diagnosis of the 
severity of obstruction and validated these biomarkers in 
urine collected in a prospective blinded study. Using these 
biomarkers, they were able to predict, several months in 
advance and with 94% precision, the clinical evolution of 
neonates with UPJ obstruction. Th e combination of classical 
clinical analysis (determination of pelvic dilation, grade of 
hydronephrosis, and analysis of renal function and integrity 
using scintigraphy) and noninvasive CE-MS analysis early 
in life to diagnose and predict the clinical evolution of UPJ 
obstruction should allow early and justifi ed intervention 
and reduce the number of invasive analyses performed on 
newborns. (Nat Med 2006; 12: 398–400)
Juan Oliver
Mechanism of insulin resistance
Insulin resistance is a cardinal feature of type 2 diabetes 
as well as a wide range of other clinical and experimental 
conditions, such as pregnancy, sepsis, cancer cachexia, 
obesity, starvation, acromegaly, burn trauma, and metabolic 
syndrome. It is currently unknown why insulin resistance 
occurs in so many contexts, but epidemiological studies 
have shown that it markedly increases cardiovascular 
disease risk. It also is unknown whether the various insults 
that trigger insulin resistance act through a common 
mechanism or use distinct cellular pathways. In an exciting 
communication, Houstis et al. report a genomic analysis of 
two cellular models of insulin resistance, one induced by 
treatment with the cytokine tumor necrosis factor-α and 
the other induced by the glucocorticoid dexamethasone.1 
Gene expression analysis indicated that genes related to 
generation of reactive oxygen species (ROS) levels were 
increased in both models, and this was confi rmed through 
measures of cellular redox state. Additional evidence that 
ROS are involved in insulin resistance was obtained in 
cell culture experiments using six treatments designed to 
alter ROS levels, including two small molecules and four 
transgenes; all ameliorated insulin resistance to varying 
degrees. One of these treatments was tested in obese, 
insulin-resistant mice and was shown to improve insulin 
sensitivity and glucose homeostasis. Together, these fi ndings 
suggest that increased ROS levels are an important trigger 
for insulin resistance in numerous settings.
In a related publication, Du et al. show that, in the 
absence of insulin, increased oxidation of free fatty acids 
(FFAs) in aortic endothelial cells increased production of 
superoxide by the mitochondrial electron transport chain.2 
FFA-induced overproduction of superoxide activated a 
variety of proinfl ammatory signals previously implicated in 
hyperglycemia-induced vascular damage and inactivated two 
important antiatherogenic enzymes, prostacyclin synthase 
and endothelial nitric oxide synthase (eNOS). In two non-
diabetic rodent models — insulin-resistant, obese Zucker 
(fa/fa) rats and high-fat diet-induced insulin-resistant mice 
— inactivation of prostacyclin synthase and eNOS was 
prevented by inhibition of FFA release from adipose tissue; 
by inhibition of the rate-limiting enzyme for fatty acid 
oxidation in mitochondria, carnitine palmitoyltransferase I; 
and by reduction of superoxide levels. Th ese studies identify 
ROS as critical mechanisms for development as well as for 
the consequences of insulin resistance. (1Nature 2006; 440: 
944–948. 2J Clin Invest 2006; 116: 1071–1080)
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